OX2 Therapeutics was established in 2016 in order to make a transformative impact in the treatment of:
Primary Brain Tumors
Other Solid Tumors
Today there are 700,000 people living in the US with a primary brain and central nervous system tumor
78,000 of new primary brain tumors are diagnosed each year of which 25,000 will be malignant
Our Founders have dedicated their careers to solving this problem
The Genesis of OX2’s 2nd Generation Cancer Treatment
In 2012, the
of OX2 completed two human clinical trials using a vaccine (GBM-6) against a deadly form of brain cancer
The vaccine was highly effective in
, but the cancer came roaring back
Why did this happen?
After a comprehensive investigation of serial samples from the patients as they failed therapy, it was found that
samples had a heretofore little known protein called CD200 (also known as OX2)
This protein, as it turns out
the power to shut off the immune system’s response to cancer
How CD200 Suppresses the Immune System
CD200 causes immune suppression in three ways:
Tumors actively shed the CD200 protein into the circulation
Tumor associated blood vessels become lined with CD200, inactivating T-Cells (cancer fighting cells) as they try to enter the tumor environment
Current tumor derived
actually are chocked full of CD200 which quashes the immune response
OX2’s 2nd Generation Inhibitor -- Disruptive
OX2 founders set out to neutralize CD200’s power over the Immune System
by moving to a novel CD200 Checkpoint peptide inhibitor
Substantiated data demonstrates the mechanism of action in three distinct forms:
OX2 inhibitory peptide activates the immune system through a CD200 activation receptor
Anti-CD200 receptor antibodies allow the immune system army to pass through blood vessel walls, enabling cancer killing activity
(Click on the title to read more.)
CD200 in CNS tumor-induced immunosuppression: The role for CD200 pathway blockade in targeted immunotherapy.
Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy.
Try, try again. – When a homegrown cancer therapy didn’t work as anticipated, U researchers went back to the lab to find-and slove-the problem.
Brain Cancer Drug Therapy – OX2 Therapeutics Touts Method to “Turn Off” Protein that Suppresses Immune System.
Brain Tumor Research Using Pet Dogs Creates Gateway to Helping Human Patients.
U of M Spinoff Readies Clinical Trial for Promising Brain Cancer Drug Therapy.
Under NDA; OX2 will share data supporting these claims
Immunotherapy – The Promise To Cure Cancer
“This is a fundamental change in the way that we think about cancer therapy,”
said Dr. Jedd Wolchok, chief of melanoma and immunotherapeutic services at
Memorial Sloan Kettering
Researchers are challenged to overcome the complex interplay between the immune system and the immunosuppressive tumor microenvironment
Progression to a productive immune response involves passing a complex number of
that act as barriers to effective immunotherapy
hold great promise to overcome
Due to that promise, Checkpoint Inhibitors are and have been Fast Tracked through clinical trials by the FDA for solid tumors
With a successful funding OX2 can start a clinical trial with a high probability of gaining this fast track annotation
OX2’s Intellectual Property
OX2 Therapeutics has exclusive clinical / commercial license grant on the following patents from the University of Minnesota
CD200 Derived Peptide Augments Tumor Induced Suppression. 62/250,376
Use of OX2 Inhibitors Conjugated to Adjuvants to Overcome Tumor Induced Suppression, and Enhance Immune Responses. 14/788,088
Additionally, we will be granted a license to a patent application that is being completed
Finally, we have received word that one of our patent application is being fast tracked for approval by the USPTO